Harmony Biosciences Holdings annual free cash flow
2019
2020
2021
2022
2023
2024
2025
Harmony Biosciences Holdings Free Cash Flow (FCF) History (HRMY)
Harmony Biosciences Holdings reported $347.9M in free cash flow for fiscal 2025, an increase of 59.09% from the previous fiscal year, with a free cash flow margin of 40.06%.
View full Harmony Biosciences Holdings company overviewHarmony Biosciences Holdings free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $347.9M | $129.2M | +59.09% | +40.06% |
| 2024 | 2024-12-31 | $218.7M | −$407,000 | −0.19% | +30.59% |
| 2023 | 2023-12-31 | $219.1M | $74.8M | +51.83% | +37.64% |
| 2022 | 2022-12-31 | $144.3M | $46.0M | +46.85% | +32.95% |
| 2021 | 2021-12-31 | $98.3M | $101.2M | — | +32.17% |
| 2020 | 2020-12-31 | −$3.0M | $72.6M | — | −1.87% |
| 2019 | 2019-12-31 | −$75.6M | — | — | −1260.80% |
Harmony Biosciences Holdings quarterly free cash flow
Q3.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q3.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q4 2025 | 2025-12-31 | $126.0M | $51.0M | +67.95% | +51.70% |
| Q3 2025 | 2025-09-30 | $108.7M | $38.2M | +54.14% | +45.38% |
| Q2 2025 | 2025-06-30 | $79.3M | $37.3M | +88.93% | +39.56% |
| Q1 2025 | 2025-03-31 | $33.9M | $2.7M | +8.75% | +18.33% |
| Q4 2024 | 2024-12-31 | $75.0M | $11.9M | +18.94% | +37.29% |
| Q3 2024 | 2024-09-30 | $70.5M | $43.8M | +164.26% | +37.89% |
| Q2 2024 | 2024-06-30 | $42.0M | −$13.1M | −23.83% | +24.29% |
| Q1 2024 | 2024-03-31 | $31.1M | −$2.6M | −7.58% | +20.14% |
| Q3 2023 | 2023-09-30 | $63.1M | $34.3M | +119.04% | +39.37% |
| Q4 2022 | 2022-12-31 | $26.7M | −$10.9M | −28.92% | +20.79% |
| Q3 2022 | 2022-09-30 | $55.1M | $24.8M | +81.72% | +47.03% |
| Q2 2022 | 2022-06-30 | $33.7M | $15.8M | +88.54% | +31.48% |
| Q1 2022 | 2022-03-31 | $28.8M | $16.3M | +129.98% | +33.77% |
| Q4 2021 | 2021-12-31 | $37.5M | $28.7M | +324.68% | +41.15% |
| Q3 2021 | 2021-09-30 | $30.3M | — | — | +37.57% |
| Q2 2021 | 2021-06-30 | $17.9M | — | — | +24.21% |
| Q1 2021 | 2021-03-31 | $12.5M | — | — | +20.99% |
| Q3 2020 | 2020-09-30 | $8.8M | — | — | +19.38% |
Harmony Biosciences Holdings free cash flow growth trends
Over the last five reported fiscal years, free cash flow grew from −$3.0M to $347.9M, a net increase of $350.9M. Harmony Biosciences Holdings's latest reported quarter, Q4 2025, generated $126.0M in free cash flow, an increase of 67.95% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Harmony Biosciences Holdings filings at SEC.gov ↗